Please login to the form below

How to design patient services with social media within the ABPI code guidelines

In this blog, Senior Consultant Craig Moore, from the Blue Latitude Strategy team, discusses the application of the ABPI Code, including incorporating social media into digital patient services.



In the UK, the marketing of prescription medicine to health professionals and patients is carried out under strict regulatory oversight to protect and support high quality patient care. The ABPI Code of Practice for the Pharmaceutical Industry is administered by the Prescription Medicines Code of Practice Authority, and is a self-regulatory code that applies to the marketing of prescription medicines both to health professionals and the public as a whole.


When designing digital services and informational materials for prescription drugs or services, there are unique considerations that must be taken around how that information is accessed and used. In this blog, Senior Consultant Craig Moore, from the Blue Latitude Strategy team, discusses the application of the ABPI Code, including incorporating social media into digital patient services.


Do some 
market research to understand the customer needs: would patients be interested in the social media functionality; would they use it? Rounds of user research and user testing would highlight if this was important or not.
At Blue Latitude, the aim is to solve problems for clients following a number of solution design methodologies.

Host a 
PMCPA (Prescription Medicines Code of Practice Authority) training session and take the opportunity to get feedback on early solution concepts. Understand where other companies have breached the code and where you may run the risk with your own solutions. The PMCPA’s view is absolute; any company working with or providing services for the Pharma Industry needs to know the code. (Blue Latitude’s staff have all completed the introductory PMCPA training session).


Get cross-functional teams around a meeting table 
to highlight social media in the organisation. The corporate communication team handles social throughout most organisations. Silos mean that the information is not always shared. The development of the website/app should not be the main focus; the main focus should be to capture any company-wide issues or concerns about using social, and highlight areas of the code that are designed to support this. Take any objections away and incorporate them into the business case for the solution.


Consider the level of patient access
 in the kind of website/app you want to develop. Patient access will raise some red flags, especially from the pharma-covigilance teams. The fear would be that an increased perception of patients discussing product-related issues would lead to an inundation of Adverse Events or Product Complaints (AE/PC).

Initiate some monitoring pilots related to the therapy area
 in general. This will help establish a reporting process; defining clear roles and responsibilities as well as outlining clear project plans, objectives, and exit strategies. Always follow the guidelines, and go beyond them.


For example, use what you report (or consider to be) an AE/PC as a metric to demonstrate that social listening will not create an undue burden on internal resources. Once the process is established, expand monitoring into competitor products – there is no need to report AE/PC for competitors – then, move on to company-owned products.

Look at the possibility of developing a solution for closed patient communities
. The code explains how use of social media to discuss prescription medicines (for example, on Twitter) is seen as promotional. With closed patient communities, the challenge to the code/internal MLR compliance teams is to make sure to only allow access to prescribed patients. Canada, for example, uses product identification numbers and DIN to allow access to a patient programme or forum.


If you’d like to discuss digital solutions for patient communities or how the ABPI Code impacts digital services in more depth, we’d love to hear from youGet in touch!

To read more about regulations which impact marketing for Pharma, read our blog from guest poster Aurelie Pols on data security and privacy.

21st May 2015

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health
Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health
Fishawack Health adds market access and commercial strategy consultancy Skysis as part of its bold growth plans
Fishawack Health, the global healthcare communications agency, announces the acquisition of Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.
Blue Latitude Health
Perspective: the patient edition
In this issue of Perspective magazine, we explore how the industry can place a greater emphasis on patient-centricity, and how pharmaceutical companies are working with patients across the product lifecycle to develop therapies that better serve their unmet needs.
Blue Latitude Health